Molecular structure of CX-5461, CAS Number: 1138549-36-6
CX-5461 (CAS 1138549-36-6)
CAS Number:
1138549-36-6
Molecular Weight:
513.6
Molecular Formula:
C27H27N7O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CX-5461 (CAS 1138549-36-6) References
- CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage. | El Hassouni, B., et al. 2019. Molecules. 24: PMID: 31817270
- CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. | Sanij, E., et al. 2020. Nat Commun. 11: 2641. PMID: 32457376
- CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition. | Lawrence, MG., et al. 2021. Mol Cancer Ther. 20: 2140-2150. PMID: 34413130
- CX-5461 is a potent immunosuppressant which inhibits T cell-mediated alloimmunity via p53-DUSP5. | Pan, G., et al. 2022. Pharmacol Res. 177: 106120. PMID: 35131482
- CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I. | Lehman, SL., et al. 2022. Sci Rep. 12: 4059. PMID: 35260696
- CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response. | Snyers, L., et al. 2022. Sci Rep. 12: 13972. PMID: 35978024
- A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex). | Xu, H. and Hurley, LH. 2022. Bioorg Med Chem Lett. 77: 129016. PMID: 36195286
- A synthetic lethal approach to drug targeting of G-quadruplexes based on CX-5461. | Jin, M., et al. 2023. Bioorg Med Chem Lett. 91: 129384. PMID: 37339720
- Extraordinary collateral mutagenesis induced by CX-5461. | Boulton, SJ. 2024. Nat Genet. 56: 12-13. PMID: 38129540
- CX‑5461 potentiates imatinib‑induced apoptosis in K562 cells by stimulating KIF1B expression. | Dai, C., et al. 2024. Exp Ther Med. 27: 107. PMID: 38356673
Inhibitor of:
82-FIP, B-Myb, BXDC1, c-Myc, C20orf112, C21orf70, C2orf49_AI597479, C8orf13, Cdc6, cryptdin 6, D10627, D130037M23Rik, D3Ertd254e, D3Ertd751e, D930020E02Rik, DDX25, DDX27, E430018J23Rik, Ear12, EG232801, EG382639, EG384244, EG665149, ELL2, Elongin A, ESF1, FXR1, GMEB-2, GTPBP4, hDcp1b, hPMS1, INTS2, ISY1, KRR1, L-Myc, LARP7, LAS1L, LASP-1, LOC283547, LOC345630, LOC644192, LSm12, LTV1, MPP10, mrnp41, MRT4, Myc, NGP1, NHP2, NHPX, NIP7, NMD3, NOL8, Nop10, Nucleostemin, NVL, Obox1, p54/nrb, PAP-α, PAP-γ, PCID2, Pol I, Pol I/II/III RPB8, Pol II, Pol II RPB6, POLR2G, POLR3E, POLR3GL, POLR3H, POLR3K, RBM15, RBM42, RBM7, RBMY1, Ribosomal Protein L10a, Ribosomal Protein L11, Ribosomal Protein S6, RIOK2, RNA pol α, RPA135, RPA16, RPA194, RPAIN, Rpb1, Rpb4, RPL6, Rpp40, RRP7A, RRP9, RSL24D1, SPT5, SUV3, TAF I p63_TAF I p68, TBK1, TERC, TFIIB, TFIIE-β, TFIIIC90, U2 snRNP B′′, UTP11L, UTP23, WBSCR27, WDR74, YB-1, ZNF19, and ZNF593.Activator of:
BMS1, C11orf59, DDX28, DRIM, EF-G1, eIF4AIII, FBL16, Josephin-3, Nop14, Nop58, Pol III RPC39, POLR1E, Ribosomal Protein L26L1, Ribosomal Protein L8, RSL1D1, STAU1, SURF-6, and WDR12.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CX-5461, 5 mg | sc-507275 | 5 mg | $245.00 |